BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V2-receptor antagonists inhibit cyst growth and slow the decline of kidney function. METHODS: In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, we randomly assigned 1445 patients, 18 to 50 years of age, who had ADPKD with a total kidney volume of 750 ml or more and an estimated creatinine clearance of 60 ml per minute or more, in a 2:1 ratio to receive tolvaptan, a V2-receptor antagonist, at the highest of three twice-daily dose regimens that the patient found tolerable, or placebo. The primary outcome was the annual rate of change in the total kidney volume. Sequential secondary end points included a composite of time to clinical progression (defined as worsening kidney function, kidney pain, hypertension, and albuminuria) and rate of kidney-function decline. RESULTS: Over a 3-year period, the increase in total kidney volume in the tolvaptan group was 2.8% per year (95% confidence interval [CI], 2.5 to 3.1), versus 5.5% per year in the placebo group (95% CI, 5.1 to 6.0; P<0.001). The composite end point favored tolvaptan over placebo (44 vs. 50 events per 100 follow-up-years, P = 0.01), with lower rates of worsening kidney function (2 vs. 5 events per 100 person-years of followup, P<0.001) and kidney pain (5 vs. 7 events per 100 person-years of follow-up, P = 0.007). Tolvaptan was associated with a slower decline in kidney function (reciprocal of the serum creatinine level, -2.61 [mg per milliliter]-1 per year vs. -3.81 [mg per milliliter]-1 per year; P<0.001). There were fewer ADPKD-related adverse events in the tolvaptan group but more events related to aquaresis (excretion of electrolyte-free water) and hepatic adverse events unrelated to ADPKD, contributing to a higher discontinuation rate (23%, vs. 14% in the placebo group). CONCLUSIONS: Tolvaptan, as compared with placebo, slowed the increase in total kidney volume and the decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, owing to adverse events. (Funded by Otsuka Pharmaceuticals and Otsuka Pharmaceutical Development and Commercialization; TEMPO 3:4 ClinicalTrials.gov number, NCT00428948.) Copyright © 2012 Massachusetts Medical Society.
|Data di pubblicazione:||2012|
|Titolo:||Tolvaptan in patients with autosomal dominant polycystic kidney disease|
|Autore/i:||Torres, V. E.; Chapman, A. B.; Devuyst, O.; Gansevoort, R. T.; Grantham, J. J.; Higashihara, E.; Perrone, R. D.; Krasa, H. B.; Ouyang, J.; Czerwiec, F. S.; Tempo, Trial Investigators; Magistroni, Riccardo|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1056/NEJMoa1205511|
|Codice identificativo ISI:||WOS:000312531600008|
|Codice identificativo Scopus:||2-s2.0-84871303897|
|Codice identificativo Pubmed:||23121377|
|Citazione:||Tolvaptan in patients with autosomal dominant polycystic kidney disease / Torres, V. E.; Chapman, A. B.; Devuyst, O.; Gansevoort, R. T.; Grantham, J. J.; Higashihara, E.; Perrone, R. D.; Krasa, H. B.; Ouyang, J.; Czerwiec, F. S.; Tempo, Trial Investigators; Magistroni, Riccardo. - In: NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 367:25(2012), pp. 2407-2418.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
|Torres-2012-Tolvaptan in patients with autosom.pdf||Versione dell'editore (versione pubblicata)||Open Access Visualizza/Apri|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris